Cancer death rates in the UK are at their lowest level on record, 29% down from when they peaked in 1989, according to our latest data.
Around 250 in every 100,000 people died from cancer each year between 2022 and 2024. That’s 11% lower than the mortality rates just ten years earlier.
“These figures represent decades of crucial scientific breakthroughs – from vaccines that prevent cancer to kinder, more targeted treatments,” said Dr Sam Godfrey, our science engagement lead.
“Because of this, thousands more people today can make memories, reach milestones, and spend precious time with their loved ones.”
The research making the difference to cancer death rates
Cervical cancer has seen one of the biggest improvements across cancer types, with a 75% reduction in death rates over the past 50 years.
That progress is set to continue thanks to innovations like the HPV vaccine, which was first introduced in 2008 and is expected to prevent 90% of all cervical cancer cases. At least 6.5 million people have now received the vaccine in the UK, making a future where almost no one develops cervical cancer increasingly possible.
Cancer Research UK played a central role in developing and testing the HPV vaccine, which prevents cervical cancer by protecting people from high-risk forms of human papillomavirus.
Now, we’re funding LungVax, OvarianVax and LynchVax, vaccines designed to prevent cancer by training the immune system to clear out cells with the potential to become cancerous.
Research into new treatments has also played an important role in pushing down cancer death rates. We helped fund the research that led to abiraterone, a groundbreaking drug that stops prostate cancer from creating testosterone to fuel its growth. Hundreds of thousands of people worldwide use abiraterone to keep their cancer from growing, and the NHS recently made it available to thousands more people every year in England.
Our researchers also set the stage for targeted and personalised cancer treatments by discovering EGFR, a molecule that can drive lung cancer growth. Since then, it’s become possible for doctors and scientists to directly target the different DNA changes that appear in cancer cells using precision medicines. Now, we’re supporting work to upgrade these targeted drugs and find new ways to combine them with tools like immunotherapy.
Building on the progress we’ve made so far
Death rates for a number of other cancer types, including stomach cancer, testicular cancer and Hodgkin’s lymphoma, have also dropped considerably. There’s also been progress against hard-to-treat cancers, including some of those that affect the brain and central nervous system, where death rates have fallen by 6% for men and 8% for women over the past 10 years.
That’s been helped by advances like the drug temozolomide, which was developed and trialled by our researchers. Temozolomide was approved for use in the 2000s and is now helping more people with fast-growing brain tumours called glioblastomas survive the disease for longer.
Early results from our trials of temozolomide motivated researchers and doctors by showing that new drugs could make a difference for people with brain tumours, but there’s much more work to do. In 2014, we identified brain tumours as a cancer of unmet need and focused on investing in research that could help ensure more people survive them for longer, including through two Brain Tumour Centres of Excellence.
That work helped pave the way for innovative trials like 5G, which is now treating glioblastoma patients with new drug combinations matched to the genetic makeup of their individual tumour. Recently, our researchers have also made a host of important discoveries about the way brain tumours develop, grow, spread, and interact with the immune system, which could lead to more effective treatments in the years to come.